Byung-Joon Kim, Jun-Seop Shin, Byoung-Hoon Min, Jong-Min Kim, Chung-Gyu Park, Hee-Jung Kang, Eung Soo Hwang, Won-Woo Lee, Jung-Sik Kim, Hyun Je Kim, Iov Kwon, Jae Sung Kim, Geun Soo Kim, Joonho Moon, Du Yeon Shin, Bumrae Cho, Heung-Mo Yang, Sung Joo Kim, Kwang-Won Kim
Diabetes Metab J. 2024;48(6):1160-1168. Published online May 21, 2024
Background Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
Stammzell- und Betazell-Transplantation bei Diabetes mellitus Barbara Ludwig Diabetologie und Stoffwechsel.2026; 21(02): 112. CrossRef
Closed-Loop Extracorporeal Vascular Cleaning by Staged Chemical Dissolution Ilia Toli Cureus.2026;[Epub] CrossRef
Co-transplantation of pancreatic islets with adipose-derived mesenchymal stem cells in vascularized kidney ECM scaffolds to restore type 1 diabetes mellitus Minji Choi, Prayas Chakma Shanto, Md Abdullah Al Fahad, Sang-ho Bae, Byong-Taek Lee Bioactive Materials.2026; 65: 268. CrossRef
An electronic medical record-based frailty index as a locally constructed composite risk score associated with septic shock and mortality in older patients with community-acquired pneumonia Sha Huang, Yan Guo, Qiying Zhou, Xiaoli Wu, Yan Wang, Xiaoyan Chen Geriatric Nursing.2026; 73: 104259. CrossRef
Allogeneic Islet Transplantation: Chronicle of a Death Foretold? Thierry Berney, Olivier Thaunat, Ekaterine Berishvili Transplant International.2025;[Epub] CrossRef
Harmonizing International Regulatory Standards for Porcine Endogenous Retrovirus (PERV) Screening in Genetically Modified Porcine Donors for First‐in‐Human Pancreatic Islet Xenotransplantation Muhammad Umer Suleman, Muhammad Mursaleen, Umer Khalil Xenotransplantation.2025;[Epub] CrossRef